

HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED

**NOTICE REGARDING ADJUSTMENT OF CONVERSION PRICE FOR
U.S.\$600,000,000 ZERO COUPON CONVERTIBLE BONDS DUE 2026
CONVERTIBLE INTO ORDINARY SHARES OF HANSOH PHARMACEUTICAL
GROUP COMPANY LIMITED**

Notice is hereby given by Hansoh Pharmaceutical Group Company Limited (the “**Company**”) of an adjustment in the conversion price (the “**Conversion Price**”) of its U.S.\$600,000,000 zero coupon convertible bonds due 2026 (the “**Bonds**”, ISIN: XS2284144339, Common code: 228414433) convertible into ordinary shares (the “**Shares**”) of the Company as set forth below.

1. Adjustment of Conversion Price

Conversion Price prior to the adjustment	Conversion Price after the adjustment (“New Conversion Price”)
HK\$60.00 per Share	HK\$59.33 per Share

2. Effective Date for the New Conversion Price

As of September 15, 2022 (being the date after the record date for the Interim Dividend (*as defined below*))

3. Reason for the Adjustment

Adjustment of the Conversion Price was made pursuant to Condition 6(C)(3) of the terms and conditions of the Bonds due to the declaration of an interim dividend of HK5 cents per Share by the Company to its shareholders for the six months ended June 30, 2022 (the “**Interim Dividend**”). The adjustment also took into account (i) the final dividend of RMB6.51 cents per ordinary share for the year ended December 31, 2020 and (ii) the final dividend of RMB7.32 cents per ordinary share for the year December 31, 2021, the effect of which have been carried forward pursuant to the terms and conditions of the Bonds.

For and on behalf of

HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED


Name: _____

Title: Director